OncRef

Clinical Trial: NCT03407144

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:Merck Sharp & Dohme LLC
Information Provided By:Merck Sharp & Dohme LLC
Last Update Posted:2026-10-02

Study Overview

Brief Summary

This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.

Official Title

An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)

Conditions

Hodgkin Lymphoma

Intervention / Treatment

  • Biological: pembrolizumab
  • Drug: doxorubicin
  • Drug: vinblastine
  • Drug: dacarbazine
  • Drug: cyclophosphamide
  • Drug: vincristine
  • Drug: prednisone/prednisolone
  • Drug: bleomycin
  • Drug: etoposide
  • Radiation: Radiotherapy (RT)

Other Study ID Numbers

  • 3475-667
  • MK-3475-667
  • 2023-504821-38-00
  • U1111-1289-8373
  • 2017-001123-53
  • 2017
  • 2023

Start Date (Actual)

2018-04-09

Primary Completion Date (Estimated)

2027-02-12

Study Completion Date (Estimated)

2027-02-12

Enrollment (Estimated)

340

Study Type

Interventional

Phase

Phase 2